GlassScriptPhysician profile
Deborah J Tanner
NPI 1619143286
$3,404.11
in general payments reported to CMS, 2019-2025
21 companies · $80.39 in 2025
The $80.39 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $1,134 · 2023: $1,090 · 2024: $354 · 2025: $80.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,523.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $812.50 | 2021-2024 | Jot Dx, Gallant, Assurity |
| Janssen Pharmaceuticals, INC | $630.58 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $432.41 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $240.03 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.77 | 2021-2022 | |
| Amgen INC. | $217.39 | 2021-2023 | Repatha |
| Pfizer INC. | $139.98 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $89.99 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $78.50 | 2022-2023 | Amvuttra |
| Sanofi-Aventis U.S. LLC | $71.46 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $71.40 | 2021-2023 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $66.91 | 2021-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $64.51 | 2022-2023 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $46.20 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $41.26 | 2023 | Inpefa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $35.82 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.72 | 2022-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $27.09 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $24.50 | 2022 | |
| Daiichi Sankyo INC. | $23.08 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $20.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.